김효수(교수)

#!if 행정구 == null && 속령 == null
[[대한민국|{{{#!wiki style="display: inline; color: ;" dark-style="color: ;"
{{{#!wiki style="display: inline-flex; vertical-align: middle; border: .0625rem solid #ddd;" dark-style="border-color: #383b40;"
[[파일:대한민국 국기.svg|width=24]]}}} {{{#!if 출력 == null
대한민국}}}{{{#!if 출력 != null
}}}}}}]]

#!if 국명 == null && 속령 == null
[[틀:국기|{{{#!wiki style="display: inline; color: ;" dark-style="color: ;"
{{{#!wiki style="display: inline-flex; vertical-align: middle; border: .0625rem solid #ddd;" dark-style="border-color: #383b40;"
[[파일: 특별행정구기.svg|width=24]]}}} {{{#!if 출력 == null
행정구}}}{{{#!if 출력 != null
}}}}}}]]

#!if 국명 == null && 행정구 == null
[[틀:국기|{{{#!wiki style="display: inline; color: ;" dark-style="color: ;"
{{{#!wiki style="display: inline-flex; vertical-align: middle; border: .0625rem solid #ddd;" dark-style="border-color: #383b40;"
[[파일: 기.svg|width=24]]}}} {{{#!if 출력 == null
속령}}}{{{#!if 출력 != null
}}}}}}]]

||<tablewidth=100%><tablebordercolor=#f5f5f5,#2d2f34><tablebgcolor=#f5f5f5,#2d2f34>*Adipokine resistin is a key player to modulate monocytes, endothelial cells, and smooth muscle cells, leading to progression of atherosclerosis in rabbit carotid artery. Journal of the American College of Cardiology. 2011 Jan 4;57(1):99-109.

*Resistin Impairs Mitochondrial Homeostasis via Cyclase-associated Protein 1-mediated Fission, Leading to Obesity-induced Metabolic Diseases. Metabolism. 2023 Jan;138:155343.

---

<Resistin> ||

||<tablewidth=100%><tablebordercolor=#f5f5f5,#2d2f34><tablebgcolor=#f5f5f5,#2d2f34>*Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. Cell Metabolism. 2014 Mar 4;19(3):484-97.

*Resistin Regulates Inflammation and Insulin Resistance in Humans via the Endocannabinoid System. Research (Washington, D.C.). 2024 Apr 2:7:0326.

---

<CAP1> ||

||<tablewidth=100%><tablebordercolor=#f5f5f5,#2d2f34><tablebgcolor=#f5f5f5,#2d2f34>*Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. European heart journal. 2020 Jan 7;41(2):239-252.

*PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to atherosclerosis progression independently of LDL receptor. Nature Communications. 2024 Mar 30;15(1):2789.

---

<PCSK9> ||

||<tablewidth=100%><tablebordercolor=#f5f5f5,#2d2f34><tablebgcolor=#f5f5f5,#2d2f34>*Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021 Jun 26; 397(10293):2487-2496.

*Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet. 2020 Oct 10; 396(10257): 1079-1089.

*Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. Lancet. 2007 Aug 18;370(9587):567-74.

*Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet. 2004 Mar 6;363(9411):751-6.

*Dual Antiplatelet Therapy After PCI According To Bleeding Risk: The HOST-BR Trial. Lancet 2025 (in press)

---

<기타> ||